首页|Data on Pneumonia Reported by Yang Pan and Colleagues (Exploration and machine l earning model development for T2 NSCLC with bronchus infiltration and obstructiv e pneumonia/atelectasis)
Data on Pneumonia Reported by Yang Pan and Colleagues (Exploration and machine l earning model development for T2 NSCLC with bronchus infiltration and obstructiv e pneumonia/atelectasis)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News-New research on Lung Diseases and Cond itions-Pneumonia is the subject of a report. According to news reporting from Hangzhou, People's Republic of China, by NewsRx journalists, research stated, "I n the 8th edition of the American Joint Committee on Cancer (AJCC) staging syste m for Non- Small Cell Lung Cancer (NSCLC), tumors exhibiting main bronchial infil tration (MBI) near the carina and those presenting with complete lung obstructiv e pneumonia/atelectasis (P/ATL) have been reclassified from T3 to T2. Our invest igation into the Surveillance, Epidemiology, and End Results (SEER) database, sp anning from 2007 to 2015 and adjusted via Propensity Score Matching (PSM) for ad ditional variables, disclosed a notably inferior overall survival (OS) for patie nts afflicted with these conditions." The news correspondents obtained a quote from the research, "Specifically, indiv iduals with P/ATL experienced a median OS of 12 months compared to 15 months (p <0.001). In contrast, MBI patients demonstrated a slightly worse prognosis with a median OS of 22 months versus 23 months (p = 0.037), wit h both conditions significantly correlated with lymph node metastasis (All p<0.001). Upon evaluating different treatment approaches for these particular T2 NSCLC variants, while adjusting for other factors, surgery emerged as the optima l therapeutic strategy. We counted those who underwent surgery and found that co mpared to surgery alone, the MBI/(P/ATL) group experienced a much higher proport ion of preoperative induction therapy or postoperative adjuvant therapy than the non-MBI/(P/ATL) group (41.3%/54.7% vs. 36.6% ). However, for MBI patients, initial surgery followed by adjuvant treatment or induction therapy succeeded in significantly enhancing prognosis, a benefit that was not replicated for P/ATL patients."
HangzhouPeople's Republic of ChinaAs iaAtelectasisCyborgsEmerging TechnologiesEpidemiologyHealth and Medici neInfectious DiseaseLung Diseases and ConditionsMachine LearningPneumoni aPulmonologyRespiratory Tract Diseases and ConditionsRespiratory Tract Inf ectionsSurgeryTherapy
NETL
NSTL
